T Cell Lymphomas
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
Latest News
New PDT therapy for CTCL to be reviewed by FDA
The treatment has received orphan drug and fast track designations from the FDA, and orphan designation from the European Medicines Agency,...
Latest News
Pandemic caused treatment delay for half of patients with CTCL, study finds
No clinical trials exist to inform maintenance protocols in patients with cutaneous lymphomas.
Feature
Third-generation Black woman physician makes cancer research history
African American surgeon helped found ASCO and collaborated with her father to achieve lasting breakthroughs in chemotherapy.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Latest News
Pfizer offers refund if drug ‘doesn’t work’
Although Pfizer claims that its pilot program is a first in the industry, there have been others that are similar.
Conference Coverage
Blacks and Hispanics have higher inpatient use for mycosis fungoides
Findings reinforce need to maintain “higher index of suspicion” in these patients.